8-KEarnings & ResultsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Nov 1, 2012)

Filed November 1, 2012For Securities:VRTX

Summary

Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K on November 1, 2012, to report its consolidated financial results for the quarter ended September 30, 2012. The filing incorporates by reference a press release issued on the same date, which contains the detailed financial performance and operational updates for the period. Investors should refer to this press release for comprehensive information regarding Vertex's financial condition and results of operations during the third quarter of 2012. This 8-K serves as a notification of the release of these key financial figures. While the 8-K itself does not contain the detailed results, it directs investors to the attached press release as the primary source of information. Therefore, an analysis of Vertex's performance for the quarter would require reviewing the content of Exhibit 99.1, the November 1, 2012 press release.

Key Highlights

  • 1Vertex Pharmaceuticals Inc. filed a Form 8-K on November 1, 2012.
  • 2The filing's primary purpose is to report the company's consolidated financial results for the quarter ended September 30, 2012.
  • 3Exhibit 99.1, a press release dated November 1, 2012, contains the detailed financial results.
  • 4The information in the press release is incorporated by reference into the 8-K.
  • 5The filing specifies that the information in Exhibit 99.1 is not considered 'filed' for Section 18 purposes, meaning it does not automatically subject the company to liability under that section.
  • 6No specific financial figures or operational details are provided directly within the 8-K form itself; investors must consult the attached press release.
  • 7The report confirms Vertex's legal jurisdiction as Massachusetts and provides its principal executive office address in Cambridge, MA.

Frequently Asked Questions

The main purpose of this Form 8-K filing by Vertex Pharmaceuticals Inc. is to officially report its consolidated financial results for the fiscal quarter that ended on September 30, 2012. It serves as a notification to investors and the public that these results have been released.

The detailed financial results for the quarter ended September 30, 2012, are provided in a press release dated November 1, 2012, which is attached as Exhibit 99.1 to this Form 8-K filing. Investors should refer to this press release for specific financial data and operational performance.

No, the 8-K filing itself does not contain the specific financial numbers such as revenue, net income, or earnings per share. It only announces that the results have been released and incorporates by reference the press release (Exhibit 99.1) where these details can be found.

When information is furnished or incorporated by reference but not deemed 'filed' for Section 18 purposes of the Securities Exchange Act of 1934, it means the company and its officers are not subject to the strict liabilities of Section 18 for any misstatements or omissions in that specific information. This is a common distinction made for press releases furnished under Item 2.02 of Form 8-K.